The one thing does surprise me in this whole equation is how much credence the onc doc's have supposedly given to Bosulif. It's not just this CS report, but across the board. If true, it makes me question the supposed CML professionals. Do they look at the data?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.